Abstract: 4-Amino-6-(heterocyclic)picolinic acids and their derivatives; 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their derivatives; and methods of using the same as herbicides.

Abstract: A gel formulation for use in filling a wound cavity and delivering active ingredient thereto, having a pH range of 6.5 to 7.5, low bioadhesive strength and cohesive integrity and being a PVA borate gel including an active ingredient and a modulator to bind borate and/or PVA in aqueous solution through a mono-diol or di-diol formation and reduces the pH of PVA-borate hydrogels. A suitable modulator is a sugar alcohol such as mannitol and the active ingredient, a medicament suitable for topical application such as a local anaesthetic and/or an antibiotic.

Abstract: Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize ?-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.

Abstract: An object of the present invention is to provide an auxin biosynthesis inhibitor superior to L-AOPP. The object can be attained by a compound represented by general formula (I): wherein, R1 to R5 and X are the same as defined in the specification or a salt or solvate thereof.

Abstract: In order to provide a compound that shows a strong effect on controlling a plant disease, a triazole compound of the present invention (i) is a compound in which —OH group, —R2 group, and CH2—Ar group are bonded in cis configuration with a cyclopentane, (ii) is (?)-enantiomer or (+) enantiomer, and (iii) is represented by Formula (I): (wherein R1 represents an alkyl group; R2 represents a haloalkyl group; and Ar represents a substituted/unsubstituted aromatic hydrocarbon group or a substituted/unsubstituted aromatic heterocyclic group.

Abstract: The present invention relates to the use of dithiine-tetracarboximide compounds of formula I as defined in the description, and the N-oxides, and salts thereof for combating harmful fungi and seed coated with at least one such compound. The invention also relates to novel dithiine-tetracarboximides, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound.

Abstract: Compositions and methods for enhancing plant growth and crop yield in legumes and non-legumes are described. The compositions include lipo-chitooligosaccharides in combination with chitins/chitosans or in combination with flavonoid compounds or in combination with a herbicide. The method includes applying the compositions to seeds and/or plants either concomitantly or sequentially.

Abstract: In order to provide a novel azole derivative, an azole derivative of the present invention is an azole derivative represented by a general formula (V?). (where R6 and R7 independently represent a hydrogen atom, a C1-C4 alkyl group, a phenyl group, or a benzyl group; X represents a halogen atom, a C1-C4 alkyl group, a haloalkyl group, an alkoxy group or a haloalkoxy group, a phenyl group, a cyano group, or a nitro group; m represents an integer of 0 to 5; and A represents a nitrogen atom or a methyne group.

Abstract: A composition comprising a macromer that can be in situ polymerized into a hydrogel wound dressing directly on a wound and one or more antimicrobial agents intended to achieve bacteriostasis and/or be bacteriocidal. The antimicrobial agent is released upon application and trapped in the hydrogel upon its formation and also released over a period of time into the wound.

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: Described are novel monocationic polyhydroxyl compounds and their uses in personal care compositions.

Abstract: This invention provides the herbicidal active ingredient, a dimethylamine salt crystal of N-phosphonomethyl glycine (glyphosate), its preparation process and a solid formulation containing the crystalline dimethylamine salt of glyphosate as well as its application. Said preparation process comprises adding glyphosate and a suitable amount of solvent into a conventional reactor and introducing a dimethylamine gas for reaction, wherein the reaction temperature is controlled between 5 and 90° C. After the completion of the reaction, the temperature is reduced slowly to a certain value, a crystalline dimethylamine salt of glyphosate is precipitated (or precipitated after a crystal seed is added).

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.

Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising a modified release portion containing tamsulosin or a pharmaceutically acceptable salt thereof, and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance. In the pharmaceutical composition, the dissolution rate of each drug (in particular, solifenacin contained in the immediate release portion) is similar to those of the current single drug formulations, and the maximum percentage of drag dissolution of each drug (in particular, solifenacin contained in the immediate release portion) is 90% or more. Therefore, the pharmaceutical composition is a single formulation (i.e., a combined formulation) with a bioavailability equivalent to those of the current single drug formulations.